Verigraft is developing decellularized vein grafts to treat chronic venous insufficiency without immunosuppression, with trials underway.

Explore how process intensification is fundamentally transforming bioprocessing and defining the future of next-gen ...

As pipelines diversify and new conjugation approaches emerge, facilities designed around today’s processes must be prepared ...

Ab platforms built the industry, but complex formats like ADCs, bsAbs, and Fc fusions demand new CMC and facility strategies.

The distinctive properties of USP's mAb reference standards show utility for qualifying and monitoring methods for thermal ...

Incremental, vertical implementation of data systems and process analytics will help biomanufacturers work toward autonomous ...

NIBRT and San Jacinto College's biotech center in Houston train students for in-demand biomanufacturing and cell and gene therapy careers.

On 27 October 2026, B2B pharma company Adalvo announced its acquisition of a romiplostim biosimilar program from India-based ...

After a “regular review of its global operations” the firm will divest the Waterford facility by 2026. The business will be gradually transferred to its 37,000-square-meter aseptic operations facility ...

MabCare is also eligible for low-to-mid single-digit royalties. The deal is Day One’s first foray into antibody drug conjugates (ADCs). The US Food and Drug Administration (FDA) approved an ...

Figure 1A: Antibody–drug conjugate (ADC) structure and delivery pathways; linker chemistry determines the mechanism by which cytotoxin release occurs. This schematic shows a monoclonal antibody (MAb) ...

Graphical Abstract: We developed a mechanistic model to simulate purification of a viral-protein complex by cation-exchange chromatography on the “wrong side” of the molecule’s isoelectric point (in a ...